TECNOLOGÍAS APLICADAS A ONCOLOGÍA Y TERÁPIA GÉNICA
Grupos de investigación IBS-A-01
TECNOLOGÍAS APLICADAS A ONCOLOGÍA Y TERÁPIA GÉNICA
El grupo de Investigación creado en el año 1990 bajo la dirección de Dña. Antonia Aránega Jiménez se ha consolidado a lo largo de los últimos años gracias a la ampliación continúa de su plantilla investigadora y del personal en formación. Su objetivo en los últimos años se ha centrado en el desarrollo de nuevas estrategias para el tratamiento del cáncer a nivel experimental y con una finalidad de aplicación en clínica incluyendo la aplicación de sistemas nanotecnológicos, el desarrollo de sistemas diagnósticos en cáncer basados en las nuevas tecnologías incluyendo la determinación de marcadores génicos, proteicos y basados en la metabolómica, el estudio de las cáncer stem cells, sus mecanismos de resistencia y su relevancia como diana nuevas terapias, la determinación de nuevas moléculas/extractos de origen vegetal con capacidad terapéutica o preventiva frente al cáncer y el avance en aspectos relacionados con la biomedicina regenerativa especialmente en sistema nervioso y musculoesquelético.
Lineas de investigación
- Análisis de la utilidad social de la biociencia en función de las patentes: evaluación de su calidad
- Biomedicina regenerativa: utilización de células madre de grasa para la obtención de miocardiocitos
- Células madre tumorales: mecanismos de resistencia a drogas
- Desarrollo de nanoplataformas funcionalizadas para la mejora del tratamiento del cáncer
- Desarrollo de nuevos agentes antitumorales a partir de extractos naturales
- Desarrollo de nutracéuticos con valor terapéutico y preventivo en cáncer de colon
- Nuevos biomarcadores diagnósticos y pronósticos en cáncer de colon y páncreas
- Terapia génica basada en genes suicidas
Palabras clave
cáncer, terapia génica, nanotecnología, biomarcadores, nutracéuticos, extractos naturales, patentes
| Miembro |
|---|
| DOELLO GONZÁLEZ, KEVIN |
| CABEZA MONTILLA, LAURA |
| GARCÍA PINEL, BEATRIZ |
| LUQUE UCEDA, CRISTINA |
| GUZMAN CARRASCO, ANA ISABEL |
| JIMÉNEZ LUNA, CRISTINA |
| QUIÑONERO MUÑOZ, FRANCISCO JOSÉ |
| VÉLEZ FERNÁNDEZ, MARÍA CELIA |
| CLARES NAVEROS, BEATRIZ |
| FUEL HERRERA, MARCO ORLANDO |
| RODRÍGUEZ SERRANO, FERNANDO |
| CEPERO MARTÍN, ANA |
| DIEGUEZ CASTILLO, CARMELO |
| ORTIZ QUESADA, RAÚL |
| RAMA BALLESTEROS, ANA ROSA |
| FERNÁNDEZ BARBERO, JUAN EMILIO |
| CABA PÉREZ, OCTAVIO |
| PEÑA CONTRERAS, MARÍA MERCEDES |
| ARIAS MEDIANO, JOSÉ LUIS |
| MELGUIZO ALONSO, CONSOLACIÓN |
| PERAZZOLI, GLORIA |
| HERNÁNDEZ PÉREZ, ROSA |
| PRADOS SALAZAR, JOSÉ CARLOS |
| RUIZ MARTÍNEZ, Mª ADOLFINA |
| MESAS HERNÁNDEZ, CRISTINA |
Inventores: FRANCISCO JAVIER GALLEGO ROJO,JOSE ANTONIO MORALES MOLINA,BEATRIZ CLARES NAVEROS,PEDRO JOSE ACOSTA ROBLES
Título: SOLUCION PARA RESECCION ENDOSCOPICA
Código: P201630003
Inventores: AGUILERA GOMEZ MARGARITA; ARANEGA JIMENEZ ANTONIA; CALLEJA HERNANDEZ MIGUEL ANGEL ; CARRASCO PARDO ESTHER ; ESTEBAN RODRIGUEZ MARIANO ; GARCIA CHAVES MARIA ANGEL ; JIMENEZ GONZALEZ GEMA ; MARCHAL CORRALES JUAN ANTONIO ;
Título: METODO DE OBTENCION DE DATOS UTILES PARA EVALUAR LA RESPUESTA AL TRATAMIENTO CON 5-FLUOROURACILO (5-FU)
Código: P201130247
Inventores: J. Prados; A. Aránega; C. Melguizo; R. Ortiz; A. Ruiz; V. Gallardo; J.L. Arias; A.R. Rama; J.R. Delgado; R. Luque; E. González
Título: NANO-1
Código: P201130122
Inventores: ARANEGA JIMENEZ ANTONIA ; BOULAIZ HOURIA ; CAMPOS ROSA JOAQUIN MARIA ; CATIVIELA MARIN CARLOS ; CHOQUESILLO-LAZARTE DUANE; CONEJO GARCIA ANA ; CRUZ LOPEZ OLGA ; GARCIA CHAVES MARIA ANGEL ; GARCIA RUIZ JUAN MANUEL ; JIMENEZ SANZ ANA ISABEL; MARCHAL
Título: DIANAS BENZOHETEROEPINICOS
Código: P201030415
Inventores: A. Aránega; ALVAREZ DE MANZANEDA ROLDAN ENRIQUE; CHAHBOUN RACHID; F. Rodríguez Serrano; I. Messouri; H. Boulaiz; J.A. Marchal; C. Melguizo; M. Perán; J. Prados ;
Título: ANALOGOS SINTETICOS DE MEROSESQUITERPENOS Y COMPUESTOS RELACIONADOS CON ACTIVIDAD ANTITUMORAL
Código: P201050019
Inventores: Campos JM; Lopez l; Marchal JA; Boulaiz H; Aránega A; Gallo MA; Espinosa A; Rodríguez-Serrano F; Conejo, Ana
Título: NUEVAS (RS)- 7- O 9- (1,2,3,5- TETRAHIDRO-4,1-BENZOCAZEPIN-3-IL)-7H O9H-PURINAS CON ACTIVIDAD ANTITUMORAL
Código: P200802431
Inventores: J.C. Prados; C. Melguizo; R. Ortiz; A.R. Rama; H. Boulaiz; A. Aránega
Título: Gen E para el tratamiento antitumoral
Código: P200801167
Inventores: ARANEGA JIMENEZ ANTONIA ; CAMPOS ROSA JOAQUIN ; ESPINOSA UBEDA ANTONIO ; GALLO MEZO MIGUEL ANGEL ; GOMEZ VIDAL JOSE ANTONIO ; NUNEZ CARRETERO M DEL CARMEN; MARCHAL CORRALES JUAN ANTONIO; Rodriguez-Serrano F ;
Título: (2,3-DIHIDRO-5H-1,4-BENZODIHETEROEPIN-3-IL)PURINAS CON ACTIVIDAD ANTITUMORAL
Código: P200601538
Martín-Blázquez A, Díaz C, González-Flores E, Franco-Rivas D, Jiménez-Luna C, Melguizo C, Prados J, Genilloud O, Vicente F, Caba O, Pérez Del Palacio J
Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer.
Scientific reports, 2019; 9(1); 20198
FI: 4.011; Q1 / D3
Egea JM, Cabeza L, Ortiz R, Rama AR, Melguizo C, Prados J
Double origin of the extensor hallucis longus muscle: a case report.
Surgical and radiologic anatomy : SRA, 2019; 41(12); 1421-1423
FI: 1.039; Q4 / D10
Sánchez AB, Calpena AC, Mallandrich M, Clares B
Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments.
Pharmaceutics, 2019; 11(12);
FI: 4.773; Q1 / D3
Quiñonero F, Mesas C, Doello K, Cabeza L, Perazzoli G, Jimenez-Luna C, Rama AR, Melguizo C, Prados J
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.
Cancer biology & medicine, 2019; 16(4); 688-699
FI: 4.467; Q1 / D3
El-Hammadi MM, Arias JL
An update on liposomes in drug delivery: a patent review (2014-2018).
Expert opinion on therapeutic patents, 2019; 29(11); 891-907
FI: 3.699; Q1 / D2
Guadix JA, López-Beas J, Clares B, Soriano-Ruiz JL, Zugaza JL, Gálvez-Martín P
Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.
Pharmaceutics, 2019; 11(11);
FI: 4.421; Q1 / D3
Ortiz R, Cabeza L, Perazzoli G, Jimenez-Lopez J, García-Pinel B, Melguizo C, Prados J
Nanoformulations for glioblastoma multiforme: a new hope for treatment.
Future medicinal chemistry, 2019; 11(18); 2459-2480
FI: 3.617; Q2 / D4
Oliver JA, Gómez-Millán J, Medina JA, Cabeza L, Perazzoli G, Jimenez-Luna C, Doello K, Ortiz R
O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications
Balkan medical journal, 2019; 36(5); 283-286
FI: 1.203; Q3 / D7
Fernández-Campos F, Clares B, Rodríguez-Lagunas MJ, Jauregui O, Casals I, Calpena AC
Ex-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration.
Pharmaceutics, 2019; 11(9);
FI: 4.773; Q1 / D3
Jabalera Y, Garcia-Pinel B, Ortiz R, Iglesias G, Cabeza L, Prados J, Jimenez-Lopez C, Melguizo C
Oxaliplatin-Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study.
Pharmaceutics, 2019; 11(8);
FI: 4.773; Q1 / D3
Sosa L, Calpena AC, Silva-Abreu M, Espinoza LC, Rincón M, Bozal N, Domenech O, Rodríguez-Lagunas MJ, Clares B
Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis.
Pharmaceutics, 2019; 11(7);
FI: 4.773; Q1 / D3
Espinoza LC, Silva-Abreu M, Calpena AC, Rodríguez-Lagunas MJ, Fábrega MJ, Garduño-Ramírez ML, Clares B
Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases.
Nanomedicine : nanotechnology, biology, and medicine, 2019; 19; 115-125
FI: 5.57; Q1 / D3
Soriano JL, Calpena AC, Souto EB, Clares B
Therapy for prevention and treatment of skin ionizing radiation damage: a review.
International journal of radiation biology, 2019; 95(5); 537-553
FI: 2.266; Q1 / D5
Contreras-Cáceres R, Cabeza L, Perazzoli G, Díaz A, López-Romero JM, Melguizo C, Prados J
Electrospun Nanofibers: Recent Applications in Drug Delivery and Cancer Therapy.
Nanomaterials (Basel, Switzerland), 2019; 9(4);
FI: 4.034; Q2 / D5
García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.
Nanomaterials (Basel, Switzerland), 2019; 9(4);
FI: 4.034; Q2 / D5
Jiménez-López J, El-Hammadi MM, Ortiz R, Cayero-Otero MD, Cabeza L, Perazzoli G, Martin-Banderas L, Baeyens JM, Prados J, Melguizo C
A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer.
Pharmacological research, 2019; 141; 451-465
FI: 5.574; Q1 / D2
Rivera-Izquierdo M, Cabeza L, Láinez-Ramos-Bossini A, Quesada R, Perazzoli G, Alvarez P, Prados J, Melguizo C
An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders.
Expert opinion on biological therapy, 2019; 19(3); 233-248
FI: 3.585; Q2 / D5
Espinoza LC, Silva-Abreu M, Clares B, Rodríguez-Lagunas MJ, Halbaut L, Cañas MA, Calpena AC
Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil.
Pharmaceutics, 2019; 11(2);
FI: 4.773; Q1 / D3
Gaspar DP, Vital J, Leiva MC, Gonçalves LM, Taboada P, Remuñán-López C, Vítor J, Almeida AJ
Transfection of pulmonary cells by stable pDNA-polycationic hybrid nanostructured particles.
Nanomedicine (London, England), 2019; 14(4); 407-429
FI: 4.717; Q1 / D3
Bravo-Caparrós I, Perazzoli G, Yeste S, Cikes D, Baeyens JM, Cobos EJ, Nieto FR
Sigma-1 Receptor Inhibition Reduces Neuropathic Pain Induced by Partial Sciatic Nerve Transection in Mice by Opioid-Dependent and -Independent Mechanisms.
Frontiers in pharmacology, 2019; 10; 613
FI: 3.845; Q1 / D3
Castillo D, Galvez JM, Herrera LJ, Rojas F, Valenzuela O, Caba O, Prados J, Rojas I
Leukemia multiclass assessment and classification from Microarray and RNA-seq technologies integration at gene expression level.
PloS one, 2019; 14(2); e0212127
FI: 2.776; Q2 / D5
Hernández R, Sánchez-Jiménez E, Melguizo C, Prados J, Rama AR
Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives.
BMB reports, 2018; 51(11); 563-571
FI: 3.085; Q2 / D5
Lorente C, Cabeza L, Clares B, Ortiz R, Halbaut L, Delgado ÁV, Perazzoli G, Prados J, Arias JL, Melguizo C
Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy.
Colloids and surfaces. B, Biointerfaces, 2018; 171; 553-565
FI: 3.997; Q1 / D2
Hernández-Jiménez J, Martínez-Ortega A, Salmerón-García A, Cabeza J, Prados JC, Ortíz R, Navas N
Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles.
International journal of biological macromolecules, 2018; 118(Pt A); 511-524
FI: 3.909; Q2 / D3
Rincón M, Calpena AC, Clares B, Espina M, Garduño-Ramírez ML, Rodríguez-Lagunas MJ, García ML, Abrego G
Skin-controlled release lipid nanosystems of pranoprofen for the treatment of local inflammation and pain.
Nanomedicine (London, England), 2018; 13(19); 2397-2413
FI: 5.005; Q1 / D2
Montilla-García Á, Perazzoli G, Tejada MÁ, González-Cano R, Sánchez-Fernández C, Cobos EJ, Baeyens JM
Modality-specific peripheral antinociceptive effects of μ-opioid agonists on heat and mechanical stimuli: Contribution of sigma-1 receptors.
Neuropharmacology, 2018; 135; 328-342
FI: 4.249; Q1 / D3
Doello K, Ortiz R, Alvarez PJ, Melguizo C, Cabeza L, Prados J
Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review.
Nutrition and cancer, 2018; 70(4); 569-578
FI: 2.261; Q3 / D7
Gálvez-Martín P, Ruiz A, Clares B
Clinical application of cell, gene and tissue therapies in Spain.
Revista clinica espanola, 2018; 218(4); 199-206
FI: 1.184; Q3 / D6
Espinoza LC, Vacacela M, Clares B, Garcia ML, Fabrega MJ, Calpena AC
Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization.
CNS & neurological disorders drug targets, 2018; 17(1); 43-53
FI: 2.084; Q3 / D8
Lorente C, Arias JL, Cabeza L, Ortiz R, Prados JC, Melguizo C, Delgado ÁV, Clares-Naveros B
Nano-engineering of biomedical prednisolone liposomes: evaluation of the cytotoxic effect on human colon carcinoma cell lines.
The Journal of pharmacy and pharmacology, 2018; 70(4); 488-497
FI: 2.309; Q3 / D6
Colomina MT, Sánchez-Santed F, Conejo NM, Collado P, Salvador A, Gallo M, Pinos H, Salas C, Navarro JF, Adán A, Azpiroz A, Arias JL
The Psychoexposome: A holistic perspective beyond health and disease.
Psicothema, 2018; 30(1); 5-7
FI: 1.516; Q2 / D5
Cobos EJ, Nickerson CA, Gao F, Chandran V, Bravo-Caparrós I, González-Cano R, Riva P, Andrews NA, Latremoliere A, Seehus CR, Perazzoli G, Nieto FR, Joller N, Painter MW, Ma CHE, Omura T, Chesler EJ, Geschwind DH, Coppola G, Rangachari M, Woolf CJ, Costigan M
Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling.
Cell reports, 2018; 22(5); 1301-1312
FI: 8.032; Q1 / D2
Sanz R, Clares B, Mallandrich M, Suñer-Carbó J, Montes MJ, Calpena AC
Development of a mucoadhesive delivery system for control release of doxepin with application in vaginal pain relief associated with gynecological surgery.
International journal of pharmaceutics, 2018; 535(1-2); 393-401
FI: 3.862; Q1 / D2
Gonzalez-Flores, E; Hernandez, R; Alvarez, PJ; Cabeza, L; Perazzoli, G; Zafra, I; Melguizo, C; Prados, J; Rama, AR
DNA methylation patterns as molecular biomarkers: an overview in colorectal cancer
EUROPEAN JOURNAL OF ANATOMY, 2018; 22;
FI: 0.0; Q / D
Alvarado HL, Calpena AC, Garduño-Ramírez ML, Ortiz R, Melguizo C, Prados JC, Clares B
Improves Antioxidant and Cytotoxic Activity in Melanoma Cells.
Anti-cancer agents in medicinal chemistry, 2018; 18(6); 847-853
FI: 2.556; Q3 / D6
Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuño FM, Guillen-Ponce C, Rojas I, Aranda E, Torres C, Prados J
Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers.
PloS one, 2018; 13(4); e0194844
FI: 2.776; Q2 / D4
Cocce V, Balducci L, Falchetti ML, Pascucci L, Ciusani E, Brini AT, Sisto F, Piovani G, Alessandri G, Parati E, Cabeza L, Pessina A
Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles.
Anti-cancer agents in medicinal chemistry, 2017; 17(11); 1578-1585
FI: 2.556; Q3 / D6
López-Viota M, El-Hammadi MM, Cabeza L, Prados J, Melguizo C, Ruiz Martinez MA, Arias JL, Delgado ÁV
Development and Characterization of Magnetite/Poly(butylcyanoacrylate) Nanoparticles for Magnetic Targeted Delivery of Cancer Drugs.
AAPS PharmSciTech, 2017; 18(8); 3042-3052
FI: 2.666; Q2 / D5
Leiva MC, Ortiz R, Contreras-Cáceres R, Perazzoli G, Mayevych I, López-Romero JM, Sarabia F, Baeyens JM, Melguizo C, Prados J
Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.
Scientific reports, 2017; 7(1); 13506
FI: 4.122; Q1 / D2
Sosa L, Clares B, Alvarado HL, Bozal N, Domenech O, Calpena AC
Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis.
Nanomedicine : nanotechnology, biology, and medicine, 2017; 13(7); 2303-2312
FI: 6.5; Q1 / D1
Andrade-Carrera B, Clares B, Noé V, Mallandrich M, Calpena AC, García ML, Garduño-Ramírez ML
Cytotoxic Evaluation of (2S)-5,7-Dihydroxy-6-prenylflavanone Derivatives Loaded PLGA Nanoparticles against MiaPaCa-2 Cells.
Molecules (Basel, Switzerland), 2017; 22(9);
FI: 3.098; Q2 / D5
Pretel E, Arias JL, Cabeza L, Melguizo C, Prados J, Mallandrich M, Suñer J, Clares B
Development of biomedical 5-fluorouracil nanoplatforms for colon cancer chemotherapy: Influence of process and formulation parameters.
International journal of pharmaceutics, 2017; 530(1-2); 155-164
FI: 3.862; Q1 / D2
Sanz R, Calpena AC, Mallandrich M, Gimeno Á, Halbaut L, Clares B
Development of a buccal doxepin platform for pain in oral mucositis derived from head and neck cancer treatment.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2017; 117; 203-211
FI: 4.491; Q1 / D2
Mallandrich M, Fernández-Campos F, Clares B, Halbaut L, Alonso C, Coderch L, Garduño-Ramírez ML, Andrade B, Del Pozo A, Lane ME, Calpena AC
Developing Transdermal Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer Hydrogels.
Pharmaceutical research, 2017; 34(8); 1728-1740
FI: 3.335; Q2 / D4
Cabeza L, Ortiz R, Prados J, Delgado ÁV, Martín-Villena MJ, Clares B, Perazzoli G, Entrena JM, Melguizo C, Arias JL
Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017; 102; 24-34
FI: 3.466; Q2 / D3
Ríos Peces S, Díaz Navarro C, Márquez López C, Caba O, Jiménez-Luna C, Melguizo C, Prados JC, Genilloud O, Vicente Pérez F, Pérez Del Palacio J
Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
SLAS discovery : advancing life sciences R & D, 2017; 22(4); 348-359
FI: ; Q / D
Megías R, Arco M, Ciriza J, Saenz Del Burgo L, Puras G, López-Viota M, Delgado ÁV, Dobson JP, Arias JL, Pedraz JL
Design and characterization of a magnetite/PEI multifunctional nanohybrid as non-viral vector and cell isolation system.
International journal of pharmaceutics, 2017; 518(1-2); 270-280
FI: 3.862; Q1 / D2
El-Hammadi MM, Delgado ÁV, Melguizo C, Prados JC, Arias JL
Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
International journal of pharmaceutics, 2017; 516(1-2); 61-70
FI: 3.862; Q1 / D2
Ortiz, R; Cabeza, L; Leiva, MC; Jimenez-Lopez, J; Melguizo, C; Prados, J
Nanomedical Platform for Drug Delivery in Cancer
CURRENT ORGANIC CHEMISTRY, 2017; 21;
FI: 2.193; Q2 / D5
Contreras-Caceres, R; Leiva, M; Ortiz, R; Diaz, A; Perazzoli, G; Casado-Rodriguez, M; Melguizo, C; Baeyens, JM; Lopez-Romero, JM; Prados, J
Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines
NANO RESEARCH, 2017; 10;
FI: 7.994; Q1 / D2
Galvez-Martín P, Martin JM, Ruiz AM, Clares B
Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications.
Current pharmaceutical biotechnology, 2017; 18(5); 365-377
FI: 1.819; Q4 / D8
Caba O, Irigoyen A, Jimenez-Luna C, Benavides M, Ortuño FM, Gallego J, Rojas I, Guillen-Ponce C, Torres C, Aranda E, Prados J
Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients.
Toxicology and applied pharmacology, 2016; 311; 113-116
FI: 3.791; Q1 / D2
Rodríguez-Serrano F, Mut-Salud N, Cruz-Bustos T, Gomez-Samblas M, Carrasco E, Garrido JM, López-Jaramillo FJ, Santoyo-Gonzalez F, Osuna A
Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
International journal of nanomedicine, 2016; 11; 4777-4785
FI: 4.3; Q1 / D2
Carrasco E, Garrido JM, Álvarez PJ, Álvarez-Manzaneda E, Chahboun R, Messouri I, Melguizo C, Aránega A, Rodríguez-Serrano F
Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.
Archives of medical science : AMS, 2016; 12(5); 919-927
FI: 1.969; Q2 / D3
Provenza N, Calpena AC, Mallandrich M, Pueyo B, Clares B
Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome.
Pharmaceutical development and technology, 2016; 21(6); 755-62
FI: 1.86; Q3 / D7
Jimenez-Luna C, Prados J, Ortiz R, Melguizo C, Torres C, Caba O
Current Status of Immunotherapy Treatments for Pancreatic Cancer.
Journal of clinical gastroenterology, 2016; 50(10); 836-848
FI: 3.328; Q2 / D4
Flo A, Calpena AC, Halbaut L, Araya EI, Fernández F, Clares B
Melatonin Delivery: Transdermal and Transbuccal Evaluation in Different Vehicles.
Pharmaceutical research, 2016; 33(7); 1615-27
FI: 3.002; Q2 / D4
Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB
Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies.
International journal of pharmaceutics, 2016; 502(1-2); 161-9
FI: 3.649; Q1 / D3
Hernández-Jiménez J, Salmerón-García A, Cabeza J, Vélez C, Capitán-Vallvey LF, Navas N
The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection.
Journal of pharmaceutical sciences, 2016; 105(4); 1405-18
FI: 2.713; Q2 / D4
Parra A, Clares B, Rosselló A, Garduño-Ramírez ML, Abrego G, García ML, Calpena AC
Ex vivo permeation of carprofen from nanoparticles: A comprehensive study through human, porcine and bovine skin as anti-inflammatory agent.
International journal of pharmaceutics, 2016; 501(1-2); 10-7
FI: 3.649; Q1 / D3
Galvez-Martin, P; Sabata, R; Verges, J; Zugaza, JL; Ruiz, A; Clares, B
Mesenchymal Stem Cells as Therapeutics Agents: Quality and Environmental Regulatory Aspects
STEM CELLS INTERNATIONAL, 2016; None;
FI: 3.54; Q2 / D5
de Escalona, MM; Saez-Fernandez, E; Prados, JC; Melguizo, C; Arias, JL
Magnetic solid lipid nanoparticles in hyperthermia against colon cancer
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016; 504;
FI: 3.649; Q1 / D3
Rodriguez, J; Martin, MJ; Ruiz, MA; Clares, B
Current encapsulation strategies for bioactive oils: From alimentary to pharmaceutical perspectives
FOOD RESEARCH INTERNATIONAL, 2016; 83;
FI: 3.086; Q1 / D2
Mut-Salud, N; Alvarez, PJ; Garrido, JM; Carrasco, E; Aranega, A; Rodriguez-Serrano, F
Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016; None;
FI: 4.593; Q2 / D3
Rama AR, Jimenez-Lopez J, Cabeza L, Jimenez-Luna C, Leiva MC, Perazzoli G, Hernandez R, Zafra I, Ortiz R, Melguizo C, Prados J
Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer.
Current drug delivery, 2016; 13(6); 830-8
FI: 2.516; Q2 / D5
Parra A, Mallandrich M, Clares B, Egea MA, Espina M, García ML, Calpena AC
Design and elaboration of freeze-dried PLGA nanoparticles for the transcorneal permeation of carprofen: Ocular anti-inflammatory applications.
Colloids and surfaces. B, Biointerfaces, 2015; 136; 935-43
FI: 3.902; Q1 / D2
Sánchez A, Calpena AC, Clares B
Evaluating the Oxidative Stress in Inflammation: Role of Melatonin.
International journal of molecular sciences, 2015; 16(8); 16981-7004
FI: 3.257; Q2 / D4
Ortiz R, Cabeza L, Arias JL, Melguizo C, Álvarez PJ, Vélez C, Clares B, Áranega A, Prados J
Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer.
The AAPS journal, 2015; 17(4); 918-29
FI: 3.819; Q1 / D2
Martín-Banderas L, Muñoz-Rubio I, Prados J, Álvarez-Fuentes J, Calderón-Montaño JM, López-Lázaro M, Arias JL, Leiva MC, Holgado MA, Fernández-Arévalo M
In vitro and in vivo evaluation of Δ⁹-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy.
International journal of pharmaceutics, 2015; 487(1-2); 205-12
FI: 3.994; Q1 / D2
Rama AR, Hernandez R, Perazzoli G, Burgos M, Melguizo C, Vélez C, Prados J
Specific Colon Cancer Cell Cytotoxicity Induced by Bacteriophage E Gene Expression under Transcriptional Control of Carcinoembryonic Antigen Promoter.
International journal of molecular sciences, 2015; 16(6); 12601-15
FI: 3.257; Q2 / D4
El-Hammadi MM, Arias JL
Iron oxide-based multifunctional nanoparticulate systems for biomedical applications: a patent review (2008 - present).
Expert opinion on therapeutic patents, 2015; 25(6); 691-709
FI: 4.626; Q1 / D1
Alvarado HL, Abrego G, Souto EB, Garduño-Ramirez ML, Clares B, García ML, Calpena AC
Nanoemulsions for dermal controlled release of oleanolic and ursolic acids: In vitro, ex vivo and in vivo characterization.
Colloids and surfaces. B, Biointerfaces, 2015; 130; 40-7
FI: 3.902; Q1 / D2
Unciti-Broceta JD, Arias JL, Maceira J, Soriano M, Ortiz-González M, Hernández-Quero J, Muñóz-Torres M, de Koning HP, Magez S, Garcia-Salcedo JA
Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis.
PLoS pathogens, 2015; 11(6); e1004942
FI: 7.003; Q1 / D1
Chayboun I, Boulifa E, Mansour AI, Rodriguez-Serrano F, Carrasco E, Alvarez PJ, Chahboun R, Alvarez-Manzaneda E
First enantiospecific syntheses of marine merosesquiterpenes neopetrosiquinones a and B: evaluation of biological activity.
Journal of natural products, 2015; 78(5); 1026-36
FI: 3.662; Q1 / D2
Alvarado HL, Abrego G, Garduño-Ramirez ML, Clares B, Calpena AC, García ML
Design and optimization of oleanolic/ursolic acid-loaded nanoplatforms for ocular anti-inflammatory applications.
Nanomedicine : nanotechnology, biology, and medicine, 2015; 11(3); 521-30
FI: 5.671; Q1 / D1
Martín MJ, Calpena AC, Fernández F, Mallandrich M, Gálvez P, Clares B
Development of alginate microspheres as nystatin carriers for oral mucosa drug delivery.
Carbohydrate polymers, 2015; 117; 140-9
FI: 4.219; Q1 / D1
Alvarado HL, Abrego G, Garduño-Ramirez ML, Clares B, García ML, Calpena AC
Development and validation of a high-performance liquid chromatography method for the quantification of ursolic/oleanic acids mixture isolated from Plumeria obtusa.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015; 983-984; 111-6
FI: 2.687; Q2 / D3
Rosario M Sánchez Martin, Consolación Melguizo, Celia Vélez, María J Rodríguez, Victoria Cano Cortés, Laura Cabeza
Polystyrene nanoparticles facilitate the internalization of impermeable biomolecules in non-tumour and tumour cells from colon epithelium
J Nanopart Res, 2015; 17;
FI: 2.101; Q2 / D4
Arias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernández-Quero J, Magez S, Soriano M, García-Salcedo JA
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis.
Journal of controlled release : official journal of the Controlled Release Society, 2015; 197; 190-8
FI: 7.441; Q1 / D1
Gonzalez, C; Alvarez, PJ; Rodriguez-Serrano, F; Velez, C; Rama, AR; Aranega, AE; Prados, JC
Computer tools and collaborative translational research in the life sciences: the further advance of genomics and proteomics
EUROPEAN JOURNAL OF ANATOMY, 2015; 19;
FI: ; Q / D
Sanchez, MT; Ruiz, MA; Morales, ME
Probiotic microorganisms and health
ARS PHARMACEUTICA, 2015; 56;
FI: ; Q / D
Sanz, R; Clares, B; Mallandrich, M; Casals, I; Bellido, D; Calpena, AC
Validation of Doxepin Quantitative Determination Methods for their Application to In Vitro, Ex Vivo and In Vivo Studies
CURRENT PHARMACEUTICAL ANALYSIS, 2015; 11;
FI: 0.885; Q4 / D9
Martin, MJ; Lara-Villoslada, F; Ruiz, MA; Morales, ME
Microencapsulation of bacteria: A review of different technologies and their impact on the probiotic effects
INNOVATIVE FOOD SCIENCE & EMERGING TECHNOLOGIES, 2015; 27;
FI: 2.997; Q1 / D2
El-Hammadi MM, Arias JL
Nano-sized platforms for vaginal drug delivery.
Current pharmaceutical design, 2015; 21(12); 1633-44
FI: 3.052; Q2 / D3
Sanz R, Calpena AC, Mallandrich M, Clares B
Enhancing topical analgesic administration: review and prospect for transdermal and transbuccal drug delivery systems.
Current pharmaceutical design, 2015; 21(20); 2867-82
FI: 3.052; Q2 / D3
Farace C, Oliver JA, Melguizo C, Alvarez P, Bandiera P, Rama AR, Malaguarnera G, Ortiz R, Madeddu R, Prados J
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
PloS one, 2015; 10(7); e0134111
FI: 3.057; Q1 / D2
Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
PloS one, 2015; 10(10); e0140131
FI: 3.057; Q1 / D2
Rama AR, Aguilera A, Melguizo C, Caba O, Prados J
Tissue Specific Promoters in Colorectal Cancer.
Disease markers, 2015; 2015; 390161
FI: 2.137; Q2 / D4
Melguizo C, Cabeza L, Prados J, Ortiz R, Caba O, Rama AR, Delgado ÁV, Arias JL
Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles.
Drug design, development and therapy, 2015; 9; 6433-44
FI: 2.881; Q2 / D4
Torres C, Linares A, Alejandre MJ, Palomino-Morales RJ, Caba O, Prados J, Aránega A, Delgado JR, Irigoyen A, Martínez-Galán J, Ortuño FM, Rojas I, Perales S
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.
BioMed research international, 2015; 2015; 518284
FI: 0.0; Q4 / D10
Castán H, Ruiz MA, Clares B, Morales ME
Design, development and characterization of buccal bioadhesive films of Doxepin for treatment of odontalgia.
Drug delivery, 2015; 22(6); 869-76
FI: 4.843; Q1 / D1
Cabeza L, Ortiz R, Arias JL, Prados J, Ruiz Martínez MA, Entrena JM, Luque R, Melguizo C
Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles.
International journal of nanomedicine, 2015; 10; 1291-306
FI: 4.32; Q1 / D2
Gimeno A, Calpena AC, Sanz R, Mallandrich M, Peraire C, Clares B
Transbuccal delivery of doxepin: studies on permeation and histological investigation.
International journal of pharmaceutics, 2014; 477(1-2); 650-4
FI: 3.65; Q1 / D3
Gálvez P, Martín MJ, Calpena AC, Tamayo JA, Ruiz MA, Clares B
Enhancing effect of glucose microspheres in the viability of human mesenchymal stem cell suspensions for clinical administration.
Pharmaceutical research, 2014; 31(12); 3515-28
FI: 3.42; Q1 / D3
López Regalado ML, Clavero A, Gonzalvo MC, Serrano M, Martínez L, Mozas J, Rodríguez-Serrano F, Fontes J, Romero B, Castilla JA
Cumulative live birth rate after two single frozen embryo transfers (eSFET) versus a double frozen embryo transfer (DFET) with cleavage stage embryos: a retrospective cohort study.
Journal of assisted reproduction and genetics, 2014; 31(12); 1621-7
FI: 1.718; Q3 / D6
Provenza N, Calpena AC, Mallandrich M, Sánchez A, Egea MA, Clares B
Permeation studies through porcine small intestine of furosemide solutions for personalised paediatric administration.
International journal of pharmaceutics, 2014; 475(1-2); 208-13
FI: 3.65; Q1 / D3
Martín-Banderas L, Muñoz-Rubio I, Álvarez-Fuentes J, Durán-Lobato M, Arias JL, Holgado MÁ, Fernández-Arévalo M
Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms.
Colloids and surfaces. B, Biointerfaces, 2014; 123; 114-22
FI: 4.152; Q1 / D3
Caba O, Prados J, Ortiz R, Jiménez-Luna C, Melguizo C, Alvarez PJ, Delgado JR, Irigoyen A, Rojas I, Pérez-Florido J, Torres C, Perales S, Linares A, Aránega A
Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers.
Digestive diseases and sciences, 2014; 59(11); 2714-20
FI: 2.613; Q2 / D5
Ciurlizza C, Fernández F, Calpena AC, Lázaro R, Parra A, Clares B
Semisolid formulations containing cetirizine: human skin permeation and topical antihistaminic evaluation in a rabbit model.
Archives of dermatological research, 2014; 306(8); 711-7
FI: 1.902; Q2 / D4
Clares B, Calpena AC, Parra A, Abrego G, Alvarado H, Fangueiro JF, Souto EB
Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation.
International journal of pharmaceutics, 2014; 473(1-2); 591-8
FI: 3.65; Q1 / D3
Torres C, Perales S, Alejandre MJ, Iglesias J, Palomino RJ, Martin M, Caba O, Prados JC, Aránega A, Delgado JR, Irigoyen A, Ortuño FM, Rojas I, Linares A
Serum cytokine profile in patients with pancreatic cancer.
Pancreas, 2014; 43(7); 1042-9
FI: 2.959; Q2 / D4
Rama AR, Alvarez PJ, Madeddu R, Aranega A
ABC transporters as differentiation markers in glioblastoma cells.
Molecular biology reports, 2014; 41(8); 4847-51
FI: 2.024; Q3 / D7
López-Regalado ML, Clavero A, Gonzalvo MC, Serrano M, Martínez L, Mozas J, Rodríguez-Serrano F, Fontes J, Castilla JA
Randomised clinical trial comparing elective single-embryo transfer followed by single-embryo cryotransfer versus double embryo transfer.
European journal of obstetrics, gynecology, and reproductive biology, 2014; 178; 192-8
FI: 1.695; Q3 / D6
Carrasco E, Alvarez PJ, Prados J, Melguizo C, Rama AR, Aránega A, Rodríguez-Serrano F
Cancer stem cells and their implication in breast cancer.
European journal of clinical investigation, 2014; 44(7); 678-87
FI: 2.734; Q1 / D2
Carrasco E, Álvarez PJ, Melguizo C, Prados J, Álvarez-Manzaneda E, Chahboun R, Messouri I, Vázquez-Vázquez MI, Aránega A, Rodríguez-Serrano F
Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.
European journal of medicinal chemistry, 2014; 79; 1-12
FI: 3.447; Q1 / D2
Boulaiz H, Aránega A, Cáceres B, Blanca C, Alvarez P, Pablo A, Serrano-Rodríguez F, Fernando RS, Carrillo E, Esmeralda C, Melguizo C, Consolación M, Prados J, Jose P
A novel double-enhanced suicide gene therapy in a colon cancer cell line mediated by gef and apoptin.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2014; 28(1); 63-74
FI: 2.989; Q2 / D4
Alvarez, P; Boulaiz, H; Velez, C; Rodriguez-Serrano, F; Ortiz, R; Melguizo, C; Carrillo, E; Martinez-Amat, A; Prados, J
Qualitative and quantitative analyses of anatomists' research: evaluation of multidisciplinarity and trends in scientific production
SCIENTOMETRICS, 2014; 98;
FI: 2.183; Q1 / D2
Oliver JA, Ortiz R, Melguizo C, Alvarez PJ, Gómez-Millán J, Prados J
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
BMC cancer, 2014; 14; 511
FI: 3.362; Q2 / D4
Prados J, Melguizo C, Perazzoli G, Cabeza L, Carrasco E, Oliver J, Jiménez-Luna C, Leiva MC, Ortiz R, Álvarez PJ, Aranega A
Application of nanotechnology in the treatment and diagnosis of gastrointestinal cancers: review of recent patents.
Recent patents on anti-cancer drug discovery, 2014; 9(1); 21-34
FI: 4.295; Q1 / D2
Clares B, Biedma-Ortiz RA, Sáez-Fernández E, Prados JC, Melguizo C, Cabeza L, Ortiz R, Arias JL
Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V, 2013; 85(3 Pt A); 329-38
FI: 4.245; Q1 / D2
Hita-Contreras F, Martínez-Amat A, Lomas-Vega R, Álvarez P, Aránega A, Martínez-López E, Mendoza N
Predictive value of stabilometry and fear of falling on falls in postmenopausal women.
Climacteric : the journal of the International Menopause Society, 2013; 16(5); 584-9
FI: 2.244; Q2 / D4
Prados J, Melguizo C, Ortiz R, Perazzoli G, Cabeza L, Alvarez PJ, Rodriguez-Serrano F, Aranega A
Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs.
Anti-cancer agents in medicinal chemistry, 2013; 13(8); 1204-16
FI: 2.939; Q2 / D4
Robles-Fernández I, Rodríguez-Serrano F, Álvarez PJ, Ortiz R, Rama AR, Prados J, Melguizo C, Álvarez-Manzaneda E, Aránega A
Antitumor properties of natural compounds and related molecules.
Recent patents on anti-cancer drug discovery, 2013; 8(3); 203-15
FI: 2.863; Q2 / D4
Prados J, Archilla F, Melguizo C, Aranega A
Four accessory (supernumerary) intrathoracic ribs: a case report.
Surgical and radiologic anatomy : SRA, 2013; 35(7); 627-9
FI: 1.333; Q3 / D6
Prados J, Melguizo C, Roldan H, Alvarez PJ, Ortiz R, Arias JL, Aranega A
RNA interference in the treatment of colon cancer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013; 27(4); 317-27
FI: 2.12; Q3 / D6
Peran M, Ruiz S, Kwiatkowski W, Marchal JA, Yang SL, Aranega A, Choe S, Izpisua Belmonte JC
Activin/BMP2 chimeric ligands direct adipose-derived stem cells to chondrogenic differentiation.
Stem cell research, 2013; 10(3); 464-76
FI: 4.467; Q1 / D2
Martín-Banderas L, Sáez-Fernández E, Holgado MÁ, Durán-Lobato MM, Prados JC, Melguizo C, Arias JL
Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
International journal of pharmaceutics, 2013; 443(1-2); 103-9
FI: 3.785; Q1 / D2
Hita-Contreras F, Martínez-Amat A, Lomas-Vega R, Álvarez P, Mendoza N, Romero-Franco N, Aránega A
Relationship of body mass index and body fat distribution with postural balance and risk of falls in Spanish postmenopausal women.
Menopause (New York, N.Y.), 2013; 20(2); 202-8
FI: 2.807; Q1 / D2
Melguizo C, Prados J, Luque R, Ortiz R, Rama AR, Caba O, Rodríguez-Serrano F, Álvarez PJ, Aránega A
Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance.
Cancer chemotherapy and pharmacology, 2013; 71(2); 537-41
FI: 2.571; Q2 / D5
Alvarez P, Carrillo E, Vélez C, Hita-Contreras F, Martínez-Amat A, Rodríguez-Serrano F, Boulaiz H, Ortiz R, Melguizo C, Prados J, Aránega A
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.
BioMed research international, 2013; 2013; 312656
FI: 0.0; Q4 / D10
Berdasco M, Melguizo C, Prados J, Gómez A, Alaminos M, Pujana MA, Lopez M, Setien F, Ortiz R, Zafra I, Aranega A, Esteller M
DNA methylation plasticity of human adipose-derived stem cells in lineage commitment.
The American journal of pathology, 2012; 181(6); 2079-93
FI: 4.522; Q1 / D2
Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, Ruíz MA, Gallardo V, Aranega A
Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy.
Anti-cancer agents in medicinal chemistry, 2012; 12(9); 1058-70
FI: 2.61; Q2 / D5
Ortiz R, Prados J, Melguizo C, Rama AR, Alvarez PJ, Rodríguez-Serrano F, Caba O, Boulaiz H, Aranega A
Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie, 2012; 66(7); 563-7
FI: 2.068; Q3 / D6
Ortiz R, Melguizo C, Prados J, Álvarez PJ, Caba O, Rodríguez-Serrano F, Hita F, Aránega A
New gene therapy strategies for cancer treatment: a review of recent patents.
Recent patents on anti-cancer drug discovery, 2012; 7(3); 297-312
FI: 2.7; Q2 / D4
Hita-Contreras F, Martínez-Amat A, Ortiz R, Caba O, Alvarez P, Prados JC, Lomas-Vega R, Aránega A, Sánchez-Montesinos I, Mérida-Velasco JA
Development and morphogenesis of human wrist joint during embryonic and early fetal period.
Journal of anatomy, 2012; 220(6); 580-90
FI: 2.357; Q1 / D2
Domínguez-Franco A, González FJ, Rodríguez-Losada N, Marchal JA, Cabrera-Bueno F, Carrillo E, Gómez-Doblas JJ, Perán M, Alonso-Briales JH, Jiménez-Navarro MF, Aránega A, De Teresa Galván E, Red de Investigación Cardiovascular (RECAVA)
[Factors influencing mobilisation of endothelial progenitor cells and angiogenic cytokines after an extensive acute myocardial infarction].
Medicina clinica, 2012; 138(10); 415-21
FI: 1.399; Q2 / D5
Caba O, Rodríguez-Serrano F, Díaz-Gavilán M, Conejo-García A, Ortiz R, Martínez-Amat A, Alvarez P, Gallo MA, Campos JM, Marchal JA, Aránega A
The selective cytotoxic activity in breast cancer cells by an anthranilic alcohol-derived acyclic 5-fluorouracil O,N-acetal is mediated by endoplasmic reticulum stress-induced apoptosis.
European journal of medicinal chemistry, 2012; 50; 376-82
FI: 3.499; Q1 / D3
Marchal JA, Picón M, Perán M, Bueno C, Jiménez-Navarro M, Carrillo E, Boulaiz H, Rodríguez N, Álvarez P, Menendez P, de Teresa E, Aránega A
Purification and long-term expansion of multipotent endothelial-like cells with potential cardiovascular regeneration.
Stem cells and development, 2012; 21(4); 562-74
FI: 4.67; Q1 / D1
Álvarez P, Marchal JA, Boulaiz H, Carrillo E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R, Aranega A
5-Fluorouracil derivatives: a patent review.
Expert opinion on therapeutic patents, 2012; 22(2); 107-23
FI: 3.525; Q1 / D1
Martín-Banderas L, Alvarez-Fuentes J, Durán-Lobato M, Prados J, Melguizo C, Fernández-Arévalo M, Holgado MÁ
Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies.
International journal of nanomedicine, 2012; 7; 5793-806
FI: 3.463; Q1 / D3
Sánchez-Moreno P, Boulaiz H, Ortega-Vinuesa JL, Peula-García JM, Aránega A
Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells.
International journal of molecular sciences, 2012; 13(4); 4906-19
FI: 2.464; Q2 / D4
Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Journal of translational medicine, 2012; 10; 250
FI: 3.459; Q2 / D3
Prados J, Alvarez PJ, Melguizo C, Rodriguez-Serrano F, Carrillo E, Boulaiz H, Vélez C, Marchal JA, Caba O, Ortiz R, Rama A, Aranega A
How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment.
Current medicinal chemistry, 2012; 19(12); 1870-88
FI: 4.07; Q1 / D1
Ortiz R, Prados J, Melguizo C, Arias JL, Ruiz MA, Alvarez PJ, Caba O, Luque R, Segura A, Aránega A
5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer.
International journal of nanomedicine, 2012; 7; 95-107
FI: 3.463; Q1 / D3
Jiménez-Navarro MF, González FJ, Caballero-Borrego J, Marchal JA, Rodríguez-Losada N, Carrillo E, García-Pinilla JM, Hernández-García JM, Pérez-González R, Ramírez G, Aránega A, de Teresa Galván E, Investigadores RECAVA (Red Temática de Investigación Cooperativa de Enfermedades Cardiovasculares)
[Coronary disease extension determines mobilization of endothelial progenitor cells and cytokines after a first myocardial infarction with ST elevation].
Revista española de cardiología, 2011; 64(12); 1123-9
FI: 2.53; Q2 / D5
Jiménez-Navarro MF, Caballero-Borrego J, Rodriguez-Losada N, Cabrera-Bueno F, Marchal JA, Estebaranz J, Muñoz-García A, Perán M, Pérez R, Ramírez G, Hernández-García JM, Aránega A, de Teresa Galván E
Influence of preinfarction angina on the release kinetics of endothelial progenitor cells and cytokines during the week after infarction.
European journal of clinical investigation, 2011; 41(11); 1220-6
FI: 3.018; Q1 / D2
Melguizo C, Prados J, Rama AR, Ortiz R, Álvarez PJ, Fernández JE, Aranega A
Multidrug resistance and rhabdomyosarcoma (Review).
Oncology reports, 2011; 26(4); 755-61
FI: 1.835; Q3 / D7
Caba O, Díaz-Gavilán M, Rodríguez-Serrano F, Boulaiz H, Aránega A, Gallo MA, Marchal JA, Campos JM
Anticancer activity and cDNA microarray studies of a (RS)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine, and an acyclic (RS)-O,N-acetalic 6-chloro-7H-purine.
European journal of medicinal chemistry, 2011; 46(9); 3802-9
FI: 3.346; Q1 / D3
Conejo-García A, García-Rubiño ME, Marchal JA, Núñez MC, Ramírez A, Cimino S, García MÁ, Aránega A, Gallo MA, Campos JM
Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9H-purines.
European journal of medicinal chemistry, 2011; 46(9); 3795-801
FI: 3.346; Q1 / D3
Rama AR, Prados J, Melguizo C, Burgos M, Alvarez PJ, Rodriguez-Serrano F, Ramos JL, Aranega A
Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie, 2011; 65(4); 260-70
FI: 2.0; Q3 / D6
Perán M, Sánchez-Ferrero A, Tosh D, Marchal JA, Lopez E, Alvarez P, Boulaiz H, Rodríguez-Serrano F, Aranega A
Ultrastructural and molecular analyzes of insulin-producing cells induced from human hepatoma cells.
Cytotherapy, 2011; 13(2); 193-200
FI: 3.627; Q1 / D3
Boulaiz H, Alvarez PJ, Ramirez A, Marchal JA, Prados J, Rodríguez-Serrano F, Perán M, Melguizo C, Aranega A
Nanomedicine: application areas and development prospects.
International journal of molecular sciences, 2011; 12(5); 3303-21
FI: 2.279; Q2 / D3
Boulaiz H, Alvarez PJ, Prados J, Marchal J, Melguizo C, Carrillo E, Peran M, Rodríguez F, Ramírez A, Ortíz R, Aránega A
gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathway.
International journal of molecular sciences, 2011; 12(11); 7445-58
FI: 2.279; Q2 / D3
López-Cara LC, Conejo-García A, Marchal JA, Macchione G, Cruz-López O, Boulaiz H, García MA, Rodríguez-Serrano F, Ramírez A, Cativiela C, Jiménez AI, García-Ruiz JM, Choquesillo-Lazarte D, Aránega A, Campos JM
New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine.
European journal of medicinal chemistry, 2011; 46(1); 249-58
FI: 3.346; Q1 / D3
García MA, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, Aránega A
The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells.
PloS one, 2011; 6(8); e23887
FI: 4.092; Q1 / D2
Rama AR, Prados J, Melguizo C, Ortiz R, Alvarez PJ, Rodríguez-Serrano F, Hita F, Ramos JL, Burgos M, Aranega A
E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents.
International journal of oncology, 2010; 37(6); 1503-14
FI: 2.571; Q2 / D5
Rodríguez-Serrano F, Alvarez P, Caba O, Picón M, Marchal JA, Perán M, Prados J, Melguizo C, Rama AR, Boulaiz H, Aránega A
Promotion of human adipose-derived stem cell proliferation mediated by exogenous nucleosides.
Cell biology international, 2010; 34(9); 917-24
FI: 1.747; Q4 / D9
Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, Vélez C, Caba O, Ramos JL, Aránega A
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Cancer chemotherapy and pharmacology, 2010; 66(1); 69-78
FI: 2.759; Q2 / D4
Perán M, Marchal JA, López E, Jiménez-Navarro M, Boulaiz H, Rodríguez-Serrano F, Carrillo E, Sánchez-Espin G, de Teresa E, Tosh D, Aranega A
Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes.
Cytotherapy, 2010; 12(3); 332-7
FI: 2.925; Q2 / D4
Prados J, Melguizo C, Ortiz R, Boulaiz H, Carrillo E, Segura A, Rodríguez-Herva JJ, Ramos JL, Aránega A
Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway.
Experimental dermatology, 2010; 19(4); 363-71
FI: 4.159; Q1 / D1
Rodríguez-Serrano F, Ríos A, Marchal JA, Caba O, Martínez-Amat A, Prados J, Melguizo C, Ortiz R, Perán M, Boulaiz H, Vélez C, Alvarez P, Aránega A
Differentiation of intestinal epithelial cells mediated by cell confluence and/or exogenous nucleoside supplementation.
Cells, tissues, organs, 2010; 191(6); 478-88
FI: 2.302; Q1 / D2
Ortiz R, Prados J, Melguizo C, Rama AR, Segura A, Rodríguez-Serrano F, Boulaiz H, Hita F, Martinez-Amat A, Madeddu R, Ramos JL, Aranega A
The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.
Journal of molecular medicine (Berlin, Germany), 2009; 87(9); 899-911
FI: 5.004; Q1 / D2
Perán M, Hooper H, Marchal JA, Boulaiz H, Rodríguez-Serrano F, Velez C, Aránega A, Salas R
Cell surface immobilization of GABAA Rs in cerebellar granule cells depends on the M3/M4 cytoplasmatic loop of the alpha 1 subunit.
Cells, tissues, organs, 2009; 189(6); 420-4
FI: 3.322; Q1 / D1
Marchal JA, Núñez MC, Aránega A, Gallo MA, Espinosa A, Campos JM
Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: antiproliferative activities, cellular differentiation and apoptosis.
Current medicinal chemistry, 2009; 16(9); 1166-83
FI: 4.708; Q1 / D1
Boulaiz H, Prados J, Melguizo C, Marchal JA, Carrillo E, Peran M, Rodríguez-Serrano F, Martínez-Amat A, Caba O, Hita F, Concha A, Aránega A
Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells.
The British journal of dermatology, 2008; 159(2); 370-8
FI: 3.489; Q1 / D1
Prados J, Melguizo C, Rama A, Ortiz R, Boulaiz H, Rodriguez-Serrano F, Caba O, Rodriguez-Herva JJ, Ramos JL, Aranega A
Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells.
International journal of oncology, 2008; 33(1); 121-7
FI: 2.234; Q3 / D7
Díaz-Gavilán M, Gómez-Vidal JA, Rodríguez-Serrano F, Marchal JA, Caba O, Aránega A, Gallo MA, Espinosa A, Campos JM
Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies.
Bioorganic & medicinal chemistry letters, 2008; 18(4); 1457-60
FI: 2.531; Q2 / D4
Díaz-Gavilán M, Conejo-García A, Cruz-López O, Núñez MC, Choquesillo-Lazarte D, González-Pérez JM, Rodríguez-Serrano F, Marchal JA, Aránega A, Gallo MA, Espinosa A, Campos JM
Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-purines.
ChemMedChem, 2008; 3(1); 127-35
FI: 3.15; Q1 / D2
Marchal JA, Núñez MC, Suárez I, Díaz-Gavilán M, Gómez-Vidal JA, Boulaiz H, Rodríguez-Serrano F, Gallo MA, Espinosa A, Aránega A, Campos JM
A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.
Breast cancer research and treatment, 2007; 105(3); 237-46
FI: 4.453; Q1 / D1
Marchal JA, Boulaiz H, Rodríguez-Serrano F, Peran M, Carrillo E, Vélez C, Domínguez J, Gómez-Vidal JA, Campos J, Gallo MA, Espinosa A, Aránega A
5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation.
Medicinal chemistry (Shāriqah (United Arab Emirates)), 2007; 3(3); 233-9
FI: ; Q / D
Rodríguez-Serrano F, Marchal JA, Ríos A, Martínez-Amat A, Boulaiz H, Prados J, Perán M, Caba O, Carrillo E, Hita F, Aránega A
Exogenous nucleosides modulate proliferation of rat intestinal epithelial IEC-6 cells.
The Journal of nutrition, 2007; 137(4); 879-84
FI: 3.771; Q1 / D1
C. Núñez, F. Rodríguez-Serrano, J.A. Marchal, O. Caba, A. Aránega, M.A. Gallo, A. Espinosa, J.M. Campos.
6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs. Tetrahedron
Tetrahedron, 2007; 63;
FI: 2.869; Q1 / D2
Título del proyecto: Terapia combinada mediante el uso de nanocápsulas funcionalizadas para la eliminación selectiva de células madre tumorales de cáncer de colon.
Financiador: INSTITUTO DE SALUD CARLOS III
Nº Expediente: PI19/01478
Ejecución: 2020-2022
IP: JOSÉ CARLOS PRADOS SALAZAR
Título del proyecto: Desarrollo de un lit diagnóstico para cáncer de páncreas basado en la deección de biomarcadores en suero
Financiador: INSTITUTO DE SALUD CARLOS III
Nº Expediente: DTS17/00081
Ejecución: 2018-2019
IP: JOSÉ CARLOS PRADOS SALAZAR
Título del proyecto: Ensayos comparativos entre de extractos funcionales derivados de semillas con
efecto beneficioso frente al
cáncer de colon
derivados de semillas con
efecto beneficioso frente al
cáncer de colon
Financiador: UNIVERSIDAD DE GRANADA
Nº Expediente: PSE/17/002
Ejecución: 2017-2019
IP: JOSE CARLOS PRADOS SALAZAR
Título del proyecto: Desarrollo de un kit diagnóstico para el cáncer de páncreas basado en la detección de biomarcadores en suero
Financiador: FUNDACIÓN PÚBLICA PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL ALEJANDRO OTERO (FIBAO)
Nº Expediente: INB-0009
Ejecución: 2017-2019
IP: JOSÉ CARLOS PRADOS SALAZAR
Título del proyecto: Terapia Selectiva Frente A Cáncer de Colon Avanzado Mediante Nanoplataformas de Poli(Butilcianoacrilato)-5-Fluorouracilo Direccionadas Con Anti-Egfr y Sistemas Asesino-Suicidas
Financiador: CONSEJERIA DE SALUD
Nº Expediente: PI-0476-2016
Ejecución: 2017-2019
IP: CONSOLACIÓN MELGUIZO ALONSO
Título del proyecto: Desarrollo de Un Kit Diagnóstico para Cáncer de Páncreas Basado en la Detección de Biomarcadores en Suero
Financiador: CONSEJERIA DE SALUD
Nº Expediente: PIN-0474-2016
Ejecución: 2017-2019
IP: JOSÉ CARLOS PRADOS SALAZAR
Título del proyecto: P4VP-PACLITAXEL: Un nuevo agente farmacológico para el tratamiento del cáncer de mama
Financiador: UNIVERSIDAD DE GRANADA
Nº Expediente: UGR001/A-01
Ejecución: 2017-2018
IP: JOSE CARLOS PRADOS SALAZAR
Título del proyecto: Asociación de Nuevas Nanopartículas de Paclitaxel y Antagonistas de Los Receptores Sigma 1 en el Tratamiento de Pacientes Con Cáncer de Pulmón y Mama
Financiador: CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES
Nº Expediente: PI-0049-2012
Ejecución: 2013-2015
IP: Consolación Melguizo
Título del proyecto: Perfiles de expresión génica como valor predictivo de diagnóstico y respuesta a tratamiento en pacientes con adenocarcinoma de páncreas
Financiador: INSTITUTO DE SALUD CARLOS III
Nº Expediente: PI12/01935
Ejecución: 2013-2016
IP: ANTONIA ARANEGA JIMENEZ
Título del proyecto: Alteraciones de la metilación del ADN a nivel genómico durante la diferenciación neuronal de células madre adultas: Implicaciones en Medicina Regenerativa
Financiador: Fundación La Marató de TV3
Nº Expediente: IBS-111431
Ejecución: 2012-2014
IP: Consolación Melguizo
Título del proyecto: Desarrollo de una terapia innovadora para cáncer de colon avanzado mediante el uso de nanoplataformas funcionalizadas asociadas al gen E y 5-fluorouracilo.
Financiador: Instituto de Salud Carlos III
Nº Expediente: PI11/01862
Ejecución: 2012-2015
IP: Jose Carlos Prados
Título del proyecto: Estrategia antitumoral combinada: agentes farmacológicos y genes suicidas en modelos experimentales in vitro e in vivo.
Financiador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Nº Expediente: IBS-SAF2009-12295
Ejecución: 2010-2013
IP: ANTONIA ARANEGA
Título del proyecto: Evaluación del potencial terapéutico antitumoral de nuevos merosesquiterpenos sintéticos.
Financiador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Nº Expediente: IBS-GREIB.PYR_2010_11
Ejecución: 2010-2011
IP: FERNANDO RODRÍGUEZ
Título del proyecto: Determinación de biomarcadores en pacientes con adenocarcinoma de páncreas y expresión génica por microarrays. Estudio de correlación de la respuesta clínica a gemcitabina y Erlotinib
Financiador: Instituto de Salud Carlos III
Nº Expediente: EC08/00288
Ejecución: 2010-2013
IP: ANTONIA ARANEGA
Título del proyecto: Modelo de Regeneración Cardiaca Mediante Células Madre Mesenquimales Transdiferenciadas y Vehiculadas Por Nano-Esferas
Financiador: CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES
Nº Expediente: PI0384/08
Ejecución: 2009-2012
IP: ANTONIA ARANEGA
Título del proyecto: Alteraciones genéticas y electrocardiográficas relacionadas con la displasia arritmogénica del ventrículo derecho y su implicación en la muerte súbita en deportistas.
Financiador: MINISTERIO DE EDUCACIÓN, CULTURA Y DEPORTE
Nº Expediente: IBS-05/SAL30/08
Ejecución: 2009-2009
IP: Maria Celia Vélez
Título del proyecto: Diálogos intra e intercelulares de una célula madre.
Financiador: MINISTERIO DE EDUCACIÓN, CULTURA Y DEPORTE
Nº Expediente: IBS-CCT005-07-00191
Ejecución: 2008-2008
IP: ANTONIA ARANEGA
Título del proyecto: Desarrollo de una nueva terapia combinada para cáncer de colon.
Financiador: Universidad de Granada
Nº Expediente: IBS-UGR-30 B364 1101/2007
Ejecución: 2007-2008
IP: Jose Carlos Prados
Título del proyecto: Bioefectividad y bioeficiencia de los genes gef y apoptina en construcciones virales y no virales como modelo de terapia génica.
Financiador: MINISTERIO DE EDUCACIÓN, CULTURA Y DEPORTE
Nº Expediente: IBS-SAF2005-01228
Ejecución: 2006-2009
IP: ANTONIA ARANEGA
Título del proyecto: Diferenciación Inducida de Células Madre Como Terapia Regenerativa Miocárdica.
Financiador: CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES
Nº Expediente: IBS-TCRM 0014/2006
Ejecución: 2006-2008
IP: ANTONIA ARANEGA
